Saturday, December 23, 2006

Epirubicin-Based Regimen Treats Inflammatory Breast Cancer

Epirubicin-based induction and maintenance chemotherapy leads to relatively high long-term survival rates in women with unilateral inflammatory breast cancer, French researchers report in the December 1st issue of Cancer. Dr. Corinne Veyret of Centre Henri Becquerel, Rouen and colleagues evaluated the long-term efficacy and side effects of this treatment in 120 patients with nonmetastatic disease. The patients were randomized to high-dose fluorouracil, epirubicin and cyclophosphamide (FEC) with or without lenograstim or placebo. They also underwent surgery, radiation therapy or both. Maintenance therapy was with FEC at lower doses and no hormone therapy was employed. No differences in outcome were seen between the lenograstim and placebo groups and overall; 76 patients (63.3%) developed recurrent disease. --Click the title of this post to read the full article from its source--

Labels: , ,


Post a Comment

<< Home

/* WebRing Code */